Aprea Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $8.0M
- Price
- $0.65
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.55%
- Volume
- 12.5K
About
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Quick stats
Shares outstanding12.4M
Computed float9.0M
Float / shares72.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001781983
Websitehttps://www.aprea.com
AI Summary
AI-generated1/12
standardbullishearnings
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Aprea Therapeutics reported second-quarter 2026 financial results, highlighting an acceleration in enrollment for its Phase 1 ACESOT-1051 trial of APR-1051 and plans to expand the study into uterine serous carcinoma and platinum-resistant ovarian cancer.
The company strengthened its balance sheet with $41.2 million in cash as of June 30, 2026, up from $14.6 million at year-end 2025, providing a cash runway into the first quarter of 2028.
R&D expenses increased to $2.5 million due to the advancement of the APR-1051 trial, resulting in a net loss of $3.6 million, or $0.07 per share, compared to a net loss of $3.2 million in the prior year period.